Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. PINK /
  3. ESAIY.PINK

Eisai Co. Ltd. (ESAIY PINK) stock market data APIs

$10.51 -0.11(-1%) as of July 25, 2024
Price chart is built with Anychart

Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. It has strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Eisai Co. Ltd. Financial Data Overview

10.62
10.51
-
10.7
10.51
9.31-16.85
10 662 M
38.5417
1 142 M
741 751 M
0.0781
0.0246
-0.042
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'ESAIY',
Type: 'Common Stock',
Name: 'Eisai Co. Ltd.',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG01DR7Y0K5',
ISIN: NULL,
CUSIP: NULL,
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'March',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Drug Manufacturers - Specialty & Generic',
HomeCategory: NULL,
IsDelisted: false,
}

Eisai Co. Ltd. Fundamental Data is available in our Financial Data APIs

  • Net Revenue 741 751 M
  • EBITDA 83 483 M
  • Earnings Per Share 0.24
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Eisai Co. Ltd. Earnings via APIs

  • Latest Release 2024-05-14
  • EPS/Forecast NaN

Get Eisai Co. Ltd. End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Eisai Co. Ltd. latest news via APIs

The 3 Best Neuroscience Biotech Stocks to Buy Now

Given the high bar to developing good neuroscience drugs, firms that do so will likely succeed. Here are three top biotech stocks to buy now. 

EISAI TO BEGIN ENROLLING STUDY IN PATIENTS WITH NARCOLEPSY

NUTLEY, N.J., July 8, 2024 /PRNewswire/ -- Eisai Inc. announced today that screening for Study E2086-A001-101 (Study 101) to assess the efficacy, safety and tolerability of E2086, a novel selective o...
Do you have any questions?
support@eodhistoricaldata.com